Login to Your Account

Molecular Insight Rockets 128% on Positive Cancer Drug Data

By Donna Young

Wednesday, April 14, 2010
Although results from Molecular Insight Pharmaceuticals Inc.'s Phase II data of Onalta (Yttrium-90 edotreotide), which showed the drug improved symptoms of metastatic carcinoid tumors in refractory patients, actually published nearly two weeks ago – and more than a month ago online – it took an after-market press release Monday to awake investors to the news. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription